What changed from existing technology?
This study developed a special nanoparticle that can help treat brain tumors by combining two methods: one that uses neutron beams to kill cancer cells and another that boosts the body's immune response. The nanoparticle is designed to target the brain and carry both cancer-killing agents and immune-stimulating components.
The study introduces a novel nanoplatform that combines boron neutron capture therapy with immunomodulation, addressing limitations of current boron agents by enhancing tumor targeting and integrating immune-stimulating functions.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
OpenAlex author affiliations: Neuboron (China)
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
The nanoplatform could potentially be used for combined boron neutron capture therapy and immunomodulation in glioma treatment, offering a new approach to enhance therapeutic efficacy by addressing tumor-specific accumulation, real-time monitoring, and the immunosuppressive tumor microenvironment.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.
Evidence and sources
View paper and author affiliations
Open original researchBoron‐embedded multifunctional nanoplatform toward potential combined boron neutron capture therapy and immunomodulation in gliomaSmart Molecules · Published 2026-09-16 ↗Author institutions and listed legal entities are separated; only verified exchange and ticker data is linked.